CLEVELAND--(BUSINESS WIRE)--Neuros Medical, Inc., a medical device company announced today initial feasibility study results of their patented high frequency alternating current (HFAC) Nerve Block technology from their first patient. The study is a short-term, 30-day test per patient, focusing on chronic residual limb pain. Nearly one million patients suffer from chronic residual limb pain in the U.S.
The feasibility study is being led by Dr. Amol Soin of the Ohio Pain Clinic and Kettering Health Network. Results from the study’s first patient indicate significant pain relief was obtained via the application of HFAC Nerve Block. “While further investigation is necessary, I’m extremely pleased with the overall initial results regarding the pain reduction our first patient reported, something they have not experienced since their amputation. The patient would have preferred to continue the study past the 30 days if possible,” Dr. Soin added.
“We expect to have complete feasibility study results within the next 5-6 months,” said Jon J. Snyder, President and CEO of Neuros Medical.
About Neuros Medical, Inc.
Neuros Medical, a Cleveland, Ohio based neurostimulation company, is focused on developing proprietary neurostimulation therapies for unmet needs to patients worldwide. The Company’s patented platform technology, Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, chronic migraine, and trigeminal neuralgia.